Morgan Stanley analyst Michael Ulz maintained a Buy rating on AlloVir (ALVR – Research Report) yesterday and set a price target of $20.00. The company’s shares closed yesterday at $3.52.
According to TipRanks, Ulz is a 2-star analyst with an average return of 0.0% and a 40.99% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Rocket Pharmaceuticals, and Blueprint Medicines.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AlloVir with a $19.33 average price target, implying a 449.15% upside from current levels. In a report released yesterday, SVB Securities also maintained a Buy rating on the stock with a $19.00 price target.
See today’s best-performing stocks on TipRanks >>
ALVR market cap is currently $322.1M and has a P/E ratio of -1.54.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALVR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm’s pipeline includes ALVR106, ALVR109, ALVR108, and others. The company’s product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Read More on ALVR:
